youtube_live
Q3 2026 earnings • released • EPS miss -54.39% • Revenue miss -5.83%
See resultschevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$17.16
arrow_upward
+3.19%(+0.53) 1D
$17.01
arrow_downward
-0.87% (-0.15)bedtimeAfter hours
Closed: Nov 4, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
$17.04
High
$17.67
Low
$16.23
Mkt. cap
1.69B
Avg. vol.
3.76M
Volume
75.00
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
98.59M
No. of employees
1K
Open
$17.04
High
$17.67
Low
$16.23
Mkt. cap
1.69B
Avg. vol.
3.76M
Volume
75.00
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
98.59M
No. of employees
1K
News stories
From web sources and news partners
Yahoo Finance UK
·
17 hours ago
Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions
Benzinga
·
20 hours ago
Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs
Benzinga
·
21 hours ago
Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
marketscreener.com
·
1 day ago
Ultragenyx Pharmaceutical Q3 Loss Narrows, Revenue Rises; Shares Down Pre-Bell
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorBiotechnology
Industry-
Websiteultragenyx.com